The Vaccine and Infectious Disease Organization (VIDO) in Saskatoon is developing a vaccine to combat the Andes hantavirus strain [1].

This research follows a deadly outbreak in April 2026 aboard the cruise ship Hondius, which highlighted the global risk of the virus [3]. The urgency of the project is driven by the strain's high mortality rate and its potential for human-to-human transmission.

Three people died during the outbreak on the cruise ship [1]. The vessel had traveled from Argentina, where the Andes strain is prevalent [2]. In the aftermath of the event, five French citizens were repatriated [4].

VIDO is currently conducting three simultaneous studies to understand the virus and accelerate the development of treatments [1]. The research center in Saskatchewan is working to identify ways to neutralize the virus's impact on the human respiratory system.

Public health concerns have also reached Canada. Experts have identified one confirmed case of hantavirus within the country [5]. Additionally, there is one probable second positive case currently under investigation [5].

The international scientific community has accelerated its efforts to find vaccines as the Andes strain proves more dangerous than other hantavirus varieties. While most hantaviruses are transmitted via rodent droppings, the Andes strain is notable for its ability to spread between people, a factor that contributed to the cruise ship cluster [3].

Researchers at VIDO are utilizing advanced modeling to test vaccine candidates. This approach aims to reduce the time required to move from laboratory discovery to clinical trials, provided the current research yields viable results [1].

“Three people died during the outbreak on the cruise ship”

The shift toward developing a specific vaccine for the Andes strain reflects a growing concern over zoonotic diseases that can adapt for human-to-human transmission. Because the Hondius outbreak demonstrated how quickly a localized strain can become a multi-national health event via travel, the work at VIDO represents a critical move toward pandemic preparedness for rare but high-lethality viruses.